Hit and lead criteria in drug discovery for infectious diseases of the developing world

Nature Reviews Drug Discovery

Volumn 14, Issue 11, 2015, Pages 751-758

  Katsuno, Kei ^a   Burrows, Jeremy N ^b   Duncan, Ken ^c   Van Huijsduijnen, Rob Hooft ^b   Kaneko, Takushi ^d   Kita, Kiyoshi ^e   Mowbray, Charles E ^f   Schmatz, Dennis ^b   Warner, Peter ^c   Slingsby, B T ^a  

^a Global Health Innovative Technology (GHIT) Fund   (Japan)

^b Medicines for Malaria Venture MMV   (Switzerland)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

^d Global Alliance for TB Drug Development (TB Alliance)   (United States)

^e UNIVERSITY OF TOKYO   (Japan)

^f Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; COMMUNICABLE DISEASES; DEVELOPING COUNTRY; DRUG DEVELOPMENT; ECONOMICS; MALARIA; NEGLECTED DISEASES; NON PROFIT ORGANIZATION; TRENDS; TUBERCULOSIS;

GENERIC DRUG;

ANIMALS; COMMUNICABLE DISEASES; DEVELOPING COUNTRIES; DRUG DISCOVERY; DRUGS, GENERIC; FOUNDATIONS; HUMANS; MALARIA; NEGLECTED DISEASES; TUBERCULOSIS;

EID: 84946483813     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4683     Document Type: Review

References (82)

1. World Health Organization. Antimicrobial resistance: global report on surveillance 2014 (WHO, 2014
2. Martis, E. A., Radhakrishnan, R., & Badve, R. R. High-Throughput screening: the hits, and leads of drug discovery-An overview. J. Appl. Pharma. Sci. 1, 2-10 (2011
3. Khanna, I. Drug discovery in pharmaceutical industry: productivity challenges, and trends. Drug Discov. Today 17, 1088-1102 (2012
4. Nwaka, S., & Hudson, A. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 5, 941-955 (2006
5. Nwaka, S., et al. Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl Trop. Dis. 3, e440 (2009
6. Burrows, J. N., Hooft van Huijsduijnen, R., Möhrle, J. J., Oeuvray, C., & Wells, T. N. C. Designing the next generation of medicines for malaria control, and eradication. Malar. J. 12, 187 (2013
7. Swinney, D. C. Phenotypic versus target-based drug discovery for first in class medicines. Clin. Pharmacol. Ther. 93, 299-301 (2013
8. Eder, J., Sedrani, R., & Wiesmann, C. The discovery of first in class drugs: origins, and evolution. Nat. Rev. Drug Discov. 13, 577-587 (2014
9. Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007
10. Deng, X., et al. Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors. J. Med. Chem. 57, 5381-5394 (2014
11. Schuster, F. L. Cultivation of Plasmodium spp. Clin. Microbiol. Rev. 15, 355-364 (2002
12. Mutai, B. K., & Waitumbi, J. N. Apoptosis stalks Plasmodium falciparum maintained in continuous culture condition. Malar J. 9 (Suppl. 3), S6 (2010
13. Chatelain, E. Chagas disease drug discovery: toward a new era. J. Biomol. Screen 20, 22-35 (2015
14. Wells, T. N. C., Hooft van Huijsduijnen, R., & Van Voorhis, W. C. Malaria medicines: a glass half full? Nat. Rev. Drug Discov. 14, 1-18 (2015
15. Bosman, A., & Mendis, K. N A major transition in malaria treatment: the adoption, and deployment of artemisinin-based combination therapies. Am. J. Trop. Med. Hyg. 77, 193-197 (2007
16. Leibert, E., Danckers, M., & Rom, W. N. New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline. Ther. Clin. Risk Manag. 10, 597-602 (2014
17. Xavier, A. S., & Lakshmanan, M. Delamanid: a new armor in combating drug-resistant tuberculosis. J. Pharmacol. Pharmacother. 5, 222-224 (2014
18. Wunberg, T., et al. Improving the hit to lead process: data-driven assessment of drug-like, and lead-like screening hits. Drug Discov. Today 11, 175-180 (2006
19. Hughes, M., et al. Early drug discovery, and development guidelines: for academic researchers, collaborators, and start up companies. Assay Guidance Manual [online], http://www.ncbi.nlm.nih.gov/books/NBK92015/(2012
20. Ariey, F., et al A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505, 50-55 (2014
21. Ashley, E. A., et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 371, 411-423 (2014
22. Burrows, J. Microbiology: malaria runs rings round artemisinin. Nature 520, 628-630 (2015
23. Mbengue, A., et al A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature 520, 683-687 (2015
24. Burrows, J. N., & Waterson, D. in Third World Diseases (ed. Elliot, R. L.) 125-180 (Springer, 2011
25. Gamo, F. J., et al. Thousands of chemical starting points for antimalarial lead identification. Nature 465, 305-310 (2010
26. Guiguemde, W. A., et al. Chemical genetics of Plasmodium falciparum. Nature 465, 311-315 (2010
27. Plouffe, D., et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-Throughput screen. Proc. Natl Acad. Sci. USA 105, 9059-9064 (2008
28. Meister, S., et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334, 1372-1377 (2011
29. Angulo-Barturen, I., et al A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. PLoS ONE 3, e2252 (2008
30. Nilsen, A., et al. Quinolone 3 diarylethers: a new class of antimalarial drug. Sci. Transl. Med. 5, 177ra37 (2013
31. Winzeler, E. A., & Manary, M. J. Drug resistance genomics of the antimalarial drug artemisinin. Genome Biol. 15, 544 (2014
32. Isozumi, R., et al. Novel mutations in K13 propeller gene of artemisinin-resistant Plasmodium falciparum. Emerg. Infect. Dis. 21, 490-492 (2015
33. Tun, K. M., et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect. Dis. 15, 415-421 (2015
34. Dembele, L., et al. Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS ONE 6, e18162 (2011
35. Sinden, R. E., Carter, R., Drakeley, C., & Leroy, D. The biology of sexual development of Plasmodium: the design, and implementation of transmission-blocking strategies. Malar J. 11, 70 (2012
36. World Health Organization. Global tuberculosis report 2014. WHO [online], http://www.who.int/tb/Publications/Global-Report/en/(2014
37. Franzblau, S. G., et al. Rapid, low-Technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol. 36, 362-366 (1998
38. Cho, S. H., et al. Low-oxygen-recovery assay for high-Throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51, 1380-1385 (2007
39. Mak, P. A., et al A high-Throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem. Biol. 7, 1190-1197 (2012
40. Wayne, L. G. In vitro model of hypoxically induced nonreplicating persistence of Mycobacterium tuberculosis. Methods Mol. Med. 54, 247-269 (2001
41. Lakshminarayana, S. B., et al. Comprehensive physicochemical, pharmacokinetic, and activity profiling of anti TB agents. J. Antimicrob. Chemother. 70, 857-867 (2015
42. Dhar, N., & McKinney, J. D. Microbial phenotypic heterogeneity, and antibiotic tolerance. Curr. Opin. Microbiol. 10, 30-38 (2007
43. Mitchison, D. A. The search for new sterilizing anti-Tuberculosis drugs. Front. Biosci. 9, 1059-1072 (2004
44. Franzblau, S. G., et al. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb.) 92, 453-488 (2012
45. Silva-Miranda, M., et al. High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59, 693-697 (2015
46. Pethe, K., et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19, 1157-1160 (2013
47. Russell, D. G., Cardona, P. J., Kim, M. J., Allain, S., & Altare, F. Foamy macrophages, and the progression of the human tuberculosis granuloma. Nat. Immunol. 10, 943-948 (2009
48. Harper, J., et al. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J. Infect. Dis. 205, 595-602 (2012
49. Datta, M., et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature, and improves small molecule delivery. Proc. Natl Acad. Sci. USA 112, 1827-1832 (2015
50. Hawn, T. R., Shah, J. A., & Kalman, D. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunol. Rev. 264, 344-362 (2015
51. Moore, E. M., & Lockwood, D. N. Treatment of visceral leishmaniasis. J. Glob. Infect. Dis. 2, 151-158 (2010
52. Sundar, S., & Chakravarty, J. An update on pharmacotherapy for leishmaniasis. Expert Opin. Pharmacother. 16, 237-252 (2014
53. Molina, I., et al. Randomized trial of posaconazole, and benznidazole for chronic Chagas' disease. N. Engl. J. Med. 370, 1899-1908 (2014
54. De Rycker, M., et al. Comparison of a high-Throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay. Antimicrob. Agents Chemother. 57, 2913-2922 (2013
55. Keenan, M., et al. Selection, and optimization of hits from a high-Throughput phenotypic screen against Trypanosoma cruzi. Future Med. Chem. 5, 1733-1752 (2013
56. Pena, I., et al. New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource. Sci. Rep. 5, 8771 (2015
57. Don, R., & Ioset, J. R. Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections. Parasitology 141, 140-146 (2014
58. Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. Experimental, and computational approaches to estimate solubility, and permeability in drug discovery, and development settings. Adv. Drug Deliv. Rev. 46, 3-26 (2001
59. Gilbert, I. H. Drug discovery for neglected diseases: molecular target-based, and phenotypic approaches. J. Med. Chem. 56, 7719-7726 (2013
60. Ansari, M. T., et al. Malaria, and artemisinin derivatives: an updated review. Mini Rev. Med. Chem. 13, 1879-1902 (2013
61. Clark, R. L. Embryotoxicity of the artemisinin antimalarials, and potential consequences for use in women in the first trimester. Reprod. Toxicol. 28, 285-296 (2009
62. Toovey, S. Safety of artemisinin antimalarials. Clin. Infect. Dis. 42, 1214-1215 (2006
63. Braselmann, S., et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling, and reduces immune complex-mediated inflammation. J. Pharmacol. Exp. Ther. 319, 998-1008 (2006
64. Oberlies, N. H., & Kroll, D. J. Camptothecin, and taxol: historic achievements in natural products research. J. Nat. Prod. 67, 129-135 (2004
65. Tsang, C. K., Qi, H., Liu, L. F., & Zheng, X. F. Targeting mammalian target of rapamycin (mTOR) for health, and diseases. Drug Discov. Today 12, 112-124 (2007
66. Borel, J. F. History of the discovery of cyclosporin, and of its early pharmacological development. Wien Klin. Wochenschr. 114, 433-437 (2002
67. Slingsby, B. T., & Kurokawa, K. The Global Health Innovative Technology (GHIT) fund: financing medical innovations for neglected populations. Lancet Glob. Health 1, e184-185 (2013
68. Holmes, D. The GHIT fund shows its cards. Nat. Rev. Drug Discov. 12, 894 (2013
69. Crump, A., & Omura, S. Ivermectin, 'wonder drug' from Japan: the human use perspective. Proc. Jpn Acad., Ser. B 87, 13-28 (2011
70. Kita, K., Shiomi, K., & Omura, S. Advances in drug discovery, and biochemical studies. Trends Parasitol. 23, 223-229 (2007
71. Omura, S., & Crump, A. The life, and times of ivermectin-A success story. Nat. Rev. Microbiol. 2, 984-989 (2004
72. Strader, C. R., Pearce, C. J., & Oberlies, N. H. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J. Nat. Prod. 74, 900-907 (2011
73. Endo, A A historical perspective on the discovery of statins. Proc. Jpn Acad. Ser. B Phys. Biol. Sci. 86, 484-493 (2010
74. Tobert, J. A. Lovastatin, and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov. 2, 517-526 (2003
75. Baell, J. B., & Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries, and for their exclusion in bioassays. J. Med. Chem. 53, 2719-2740 (2010
76. McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K A common mechanism underlying promiscuous inhibitors from virtual, and high-Throughput screening. J. Med. Chem. 45, 1712-1722 (2002
77. Baell, J., & Walters, M. A. Chemistry: chemical con artists foil drug discovery. Nature 513, 481-483 (2014
78. Burrows, J. N., Leroy, D., Lotharius, J., & Waterson, D. Challenges in antimalarial drug discovery. Future Med. Chem. 3, 1401-1412 (2011
79. Ruecker, A., et al A male, and female gametocyte functional viability assay to identify biologically relevant malaria transmission-blocking drugs. Antimicrob. Agents Chemother. 58, 7292-7302 (2014
80. Orme, I. Cellular, and genetic mechanisms underlying susceptibility of animal models to tuberculosis infection. Novartis Found. Symp. 217, 112-117; discussion 117-119 (1998
81. Priest, B. T., Bell, I. M., & Garcia, M. L. Role of hERG potassium channel assays in drug development. Channels (Austin) 2, 87-93 (2008
82. Riss, T. L., et al. Cell viability assays. Assay Guidance Manual [online], http://www.ncbi.nlm.nih.gov/books/NBK53196/(2004